 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CARMEL, Ind., Aug. 29, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NeurAxis, or the Company) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlighted A Prospective Study on ...

NeurAxis Highlights Pediatric Post-Concussion Clinical Study

CARMEL, Ind., Aug. 22, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (NeurAxis, or the Company), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlights two recently published ...

NeurAxis Highlights Two Independent Studies Showing Benefits of IB-Stim in Adolescents Involving the Gut Microbiome

CARMEL, Ind., Aug. 17, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American:NRXS) (NeurAxis or the Company), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced it has generated over $8 ...

CARMEL, Ind., Aug. 17, 2023...

CARMEL, Ind., Aug. 10, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NeurAxis, or the Company) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlighted current commercial ...

NeurAxis Highlights Current Commercial Insurance Coverage with BCBS Massachusetts, BCBS South Carolina, BCBS Nebraska, and Quartz Wisconsin

CARMEL, Ind., Aug. 09, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American:NRXS) (NeurAxis or the Company), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the pricing of its ...

NeurAxis Announces Pricing of Initial Public Offering

NeurAxis, Inc. develops neuromodulation therapies to address chronic and debilitating conditions in children. Its product IB-Stim is a non-surgical device that works by sending gentle electrical impulses into cranial nerve bundles located in the ear. The company was founded by Gary Peterson and Christopher Robin Brown in 2011 and is headquartered in Carmel, IN.

Watchers	108
52-Wk Low	$3.19
52-Wk High	$6.93

Market Cap	$20.57M
Volume (M)	24,170.00
52-Wk High	$6.93
52-Wk Low	$3.19

NRXS Neuraxis Inc

About

Feed

News

Fundamentals